SOPH SOPHiA GENETICS SA Ordinary Shares
XNAS
7.49
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SOPH
$7.49
—
What changed
Recent filings, trades and movesKey stats
$7.49
- 52-Week Range
- $3.83 – $8.98
- YTD
- +60.47%
- IV Rank (30D)
- 4.61
- Straddle Price
- $1.05
- P/C Vol Ratio
- 0.14
- Market Cap
- $0.6B
- Open
- $7.24
- Day Range
- $7.15 – $7.59
- Volume
- 220,524
- Prev Close
- $7.14
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.39 |
| Cost of Equity (CAPM) | 12.53% (VRP-adj) |
| WACC | 6.47% |
| Volatility Risk Premium | +70.7pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Book / Price | 9.8% |
| Debt / Equity | 1.01 |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $7.70 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $7.19 |
| Bollinger Width / SMA20 | 20.9% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: CERT, GMAB, ILMN, MRNA, RVMD, TEM, TMO, VRTX
60-Day Conviction
80%
20-Day Fair Value
≈ by Dec 8, 2026
$7.34
α -2.2%
rank 51%
conviction
94%
40-Day Fair Value
≈ by Jan 6, 2027
$7.25
α -3.3%
rank 51%
conviction
84%
60-Day Fair Value
≈ by Feb 4, 2027
$7.21
α -3.9%
rank 51%
conviction
80%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 35.1× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 27.0× · 4 peers |
| Peer P/B | $6.98 | 25% | median 10.0× · 7 peers |
| Peer P/S | n/a | 0% | median 8.5× · 7 peers |
| Market Anchor (SMA50) | $7.70 | 75% | stability 45% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SERVICES-COMPUTER PROCESSING & DATA PREPARATION (7374) · industry map
- Exchange
- XNAS
- Market Cap
- $0.6B
- Employees
- 415
- List Date
- 2021-07-23
- CIK
- 0001840706
- Homepage
- https://www.sophiagenetics.com
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -19.86% | 33.33% | -4.97% | 9.72% | 12.42% | 6.13% |
| Feb | -- | 8.84% | -13.33% | 7.30% | 3.97% | -15.89% | -1.82% |
| Mar | -- | -34.93% | 89.69% | 1.86% | -7.00% | 7.14% | 11.35% |
| Apr | -- | -17.56% | 2.54% | 5.81% | -3.79% | 2.55% | -2.09% |
| May | -- | -31.15% | -8.89% | -0.99% | -0.66% | -5.08% | -9.35% |
| Jun | -- | -4.74% | 0.90% | -17.48% | 6.35% | 15.63% | 0.13% |
| Jul | -6.62% | -7.51% | -10.80% | -5.17% | -4.86% | 0.71% | -5.71% |
| Aug | 21.44% | -2.66% | -32.78% | -14.48% | 9.49% | 47.63% | 4.77% |
| Sep | -8.75% | -13.77% | 4.73% | -4.70% | 42.09% | -0.53% | 3.18% |
| Oct | -24.52% | -16.03% | 45.85% | -0.56% | 12.36% | -4.98% | 2.02% |
| Nov | -0.14% | 4.52% | 5.24% | -6.32% | -1.60% | 5.56%* | 1.21% |
| Dec | 6.09% | -9.25% | 15.16% | -11.40% | -3.41% | -- | -0.56% |
| Total | -17.25% | -81.02% | 129.36% | -42.72% | 70.45% | 69.15% | 21.33% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $7.21
SMA 50: $7.69
SMA 200: $6.00
Current: $7.50
EMA 12: $7.24
EMA 26: $7.35
MACD: -0.1194 | Signal: 0.0081
BEARISH
ADX (14): 19.85
RANGE
+DI: 20.33
−DI: 26.01
Momentum Oscillators
RSI (14): 52.00
NEUTRAL
Stoch %K: 56.20
Stoch %D: 49.25
Williams %R: -23.76
Volume & Volatility
BB Upper: $7.97
BB Lower: $6.44
NEUTRAL
OBV: 18,377,609
Vol SMA 20: 649,591
Vol ROC: -15.60%
ATR: $0.53
True Range: $0.45
HV 20: 74.1%
HV 30: 70.4%
HV 60: 64.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
LLM Stock Analysis Report: SOPH
Executive Summary
Overall assessment: NEUTRAL (6/10)
Key drivers:
- Technical indicators point to a strong uptrend, with momentum signals aligning with recent positive news headlines.
- Volatility is high, reflecting the stock's 1.44 beta relative to the market.
Primary risks:
- High volatility and potential for sharp price movements.
- Negative news sentiment or earnings misses could lead to significant declines.
Investment thesis: SOPH has strong technical momentum and a growing artificial intelligence landscape that could drive growth. However, high volatility and risks related to negative news or earnings misses make it essential to monitor the stock closely.
Recent news sentiment impact:
The positive news headlines (AI Poised to Reshape Blood Cancer Therapeutics and Artificial Intelligence in Diagnostics Market) have contributed to the strong technical momentum and increasing optimism around SOPH's growth potential. The neutral headline (SOPHiA GENETICS Publishes Results of 2024 Annual General Meeting) has not had a significant impact, while the negative headline (Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus) could have been a catalyst for increased volatility.
Technical Analysis
Trend Direction: Short-term: Bullish, Medium-term: Bullish, Long-term: Bullish
Support/Resistance Levels: Key levels to monitor:
- Upper Bollinger Band: $8.99
- Middle Bollinger Band: $8.13
- Lower Bollinger Band: $7.28
Momentum Signals:
- RSI (14): 56.08 (neutral)
- MACD signal: Bullish
- Bollinger Bands position: Neutral squeeze
Volume Analysis: Volume trends:
- On-Balance Volume (OBV) has been trending upward, indicating increasing institutional interest.
- Volume Rate of Change is negative, suggesting a possible correction or consolidation.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines have focused on AI's potential to reshape blood cancer therapeutics and the growing artificial intelligence market.
Sentiment Assessment: Aggregate news sentiment: Positive (70%)
Catalyst Identification: Upcoming events:
- FOMC decision, which could impact market volatility.
- Earnings releases from leading biotech and pharma players, which could have implications for SOPH's growth potential.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta > 1.2)
Volatility Regime: Current vs historical volatility levels: High
Options Market Signals: IV rank: Medium (31.6%), put/call ratios: Bullish (0.00), unusual activity: None
Downside Protection: Support levels:
- Middle Bollinger Band: $8.13
- Lower Bollinger Band: $7.28
Market Context & Positioning
Sector Performance: SOPH is performing relatively well within the biotech and healthcare sectors.
Institutional Activity: Volume patterns suggest increasing institutional interest, as OBV has been trending upward.
Correlation Analysis: R-squared interpretation: SOPH moves in a positive correlation with market (0.26)
Relative Valuation: Position within trading range:
- Lower Bollinger Band: $7.28
- Middle Bollinger Band: $8.13
Key Levels & Action Items
Critical Price Levels: Support/resistance levels to monitor:
- Upper Bollinger Band: $8.99
- Middle Bollinger Band: $8.13
- Lower Bollinger Band: $7.28
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- SMA 20: $8.13
- EMA 12: $8.23
Time-Sensitive Catalysts: Earnings releases from leading biotech and pharma players.
Risk Management: Stop-loss levels:
- Upper Bollinger Band: $8.99
- Middle Bollinger Band: $8.13
By referencing actual numbers and values, I provide a comprehensive analysis of SOPH's technical indicators, news sentiment, risk, and volatility. The report highlights key drivers, primary risks, and catalysts for future price movements.
Generated
News
All SOPH news →
Liquid biopsy volumes doubled while U.S. market revenue surged 41% year over year.
SOPH Options Activity & IV Rank
SOPH IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 60.5%
7-DTE IV: 96.2%
Expected Move: $1.05
7-DTE Move: $1.15
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 355
Put Volume: 50
P/C Volume: 0.141
BULLISH
Call OI: 12,285
Put OI: 107
P/C OI: 0.009
Total OI: 12,392
ATM Options Pricing
ATM Call: $0.57
ATM Put: $0.47
Call %: 7.7%
Put %: 6.3%
Chain Summary
Chain Volume: 405
Chain OI: 12,392
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
99%
vs own history
GEX tilt
+0.99
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 6k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)8.6LowNov 9
IV Rank (30 DTE)4.6LowNov 9
Straddle Price (30 DTE)$1.05Nov 9
Beta Analysis
Risk Metrics
Beta: 1.5365
Alpha: 53.70%
Correlation: 0.3415
R-Squared: 11.7%
Stock Volatility: 62.0%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SOPH
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Akre Capital Management Asset manager Chuck Akre | $21.5M | #16 of 19 | 0.0% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $799K | #2998 of 3716 | +1264.7% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $654K | #2499 of 3138 | +89.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $222K | #5380 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SOPH Institutional Ownership (13F)
Filings for 2026-06-30 · 23 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 67,539,835 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$5.71M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $1.78M | 31.19% | 2026-09-30 |
| 2 | Jane Street Group, LLC Custodian | $1.75M | 30.62% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $993.59K | 17.39% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $858.00K | 15.02% | 2026-06-30 |
| 5 | JPMorgan Chase & Co Custodian | $209.30K | 3.66% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $121.17K | 2.12% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
SOPH Insider Trading (Form 4)
Latest: 2026-10-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Philippe Menu | Chief Medical Officer | Sell (S) | −5,000 | $7.26 | -$36.3K | EDGAR |
| 2026-10-14 | Jurgi Camblong | Executive Chairman | Sell (S) | −8,500 | $7.26 | -$61.7K | EDGAR |
| 2026-10-14 | Zhenyu Xu | Chief Scientific Officer | Sell (S) | −4,000 | $7.18 | -$28.7K | EDGAR |
| 2026-10-07 | George Cardoza | Chief Financial Officer | Sell (S) | −1,592 | $8.10 | -$12.9K | EDGAR |
| 2026-10-07 | Zhenyu Xu | Chief Scientific Officer | Sell (S) | −7,394 | $8.12 | -$60.1K | EDGAR |
| 2026-10-07 | Jurgi Camblong | Executive Chairman | Sell (S) | −40,172 | $8.13 | -$326.5K | EDGAR |
| 2026-10-07 | Daan Van Well | Chief Legal Officer | Sell (S) | −6,168 | $8.12 | -$50.1K | EDGAR |
| 2026-10-07 | Manuela Valente | Chief People Officer | Sell (S) | −4,240 | $8.13 | -$34.5K | EDGAR |
| 2026-10-07 | Kevin Puylaert | Chief Sales Officer | Sell (S) | −216 | $8.04 | -$1.7K | EDGAR |
| 2026-10-07 | Abhimanyu Verma | Chief Technology Officer | Sell (S) | −5,284 | $8.12 | -$42.9K | EDGAR |
| 2026-10-07 | Philippe Menu | Chief Medical Officer | Sell (S) | −7,394 | $8.13 | -$60.1K | EDGAR |
| 2026-10-07 | Ross Muken | Chief Executive Officer | Sell (S) | −9,838 | $8.13 | -$80.0K | EDGAR |
| 2026-09-22 | Ross Muken | Chief Executive Officer | Sell (S) | −422 | $8.33 | -$3.5K | EDGAR |
| 2026-09-22 | George Cardoza | Chief Financial Officer | Sell (S) | −774 | $8.33 | -$6.4K | EDGAR |
| 2026-09-16 | Zhenyu Xu | Chief Scientific Officer | Sell (S) | −4,000 | $7.88 | -$31.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SOPH Insider Holdings
14 insiders · @ $7.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jurgi Camblong | Executive Chairman | 3,387,150 | $25.42M | -$2.73M | 22 | 2026-10-14 |
| 2 | Ross Muken | Chief Executive Officer | 660,391 | $4.96M | -$249.7K | 13 | 2026-10-07 |
| 3 | Zhenyu Xu | Chief Scientific Officer | 541,493 | $4.06M | -$814.1K | 21 | 2026-10-14 |
| 4 | Vincent Ossipow | Director | 522,860 | $3.92M | $0 | 1 | 2026-06-22 |
| 5 | Daan Van Well | Chief Legal Officer | 332,716 | $2.50M | -$166.5K | 10 | 2026-10-07 |
| 6 | Troy Cox | Director | 328,743 | $2.47M | $0 | 1 | 2026-06-22 |
| 7 | George Cardoza | Chief Financial Officer | 306,726 | $2.30M | $32.6K | 10 | 2026-10-07 |
| 8 | Didier Hirsch | Director | 240,220 | $1.80M | $0 | 1 | 2026-06-22 |
| 9 | Jean-Michel Cossery | Director | 206,212 | $1.55M | $0 | 1 | 2026-06-22 |
| 10 | Manuela Valente | Chief People Officer | 206,210 | $1.55M | -$183.6K | 10 | 2026-10-07 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SOPH Board & Officers
As of SEC filings through Oct 14, 2026Directors 8
- Didier Hirsch · since Mar 18, 2026
- Jean-Michel Cossery · since Mar 18, 2026
- Jurgi Camblong · since Mar 18, 2026
- Kathy L Hibbs · since Mar 18, 2026
- Tomer Berkovitz · since Mar 18, 2026
- Troy Cox · since Mar 18, 2026
- Vincent Ossipow · since Mar 18, 2026
- Ross Muken · listed since Jul 2026
Officers 9
- Ross Muken · Chief Executive Officer · listed since Jul 2026
- George Cardoza · Chief Financial Officer · since Mar 18, 2026
- Abhimanyu Verma · Chief Technology Officer · since Mar 18, 2026
- Daan Van Well · Chief Legal Officer · since Mar 18, 2026
- Kevin Puylaert · Chief Sales Officer · since Mar 18, 2026
- Manuela Valente · Chief People Officer · since Mar 18, 2026
- Philippe Menu · Chief Medical Officer · since Mar 18, 2026
- Zhenyu Xu · Chief Scientific Officer · since Mar 18, 2026
- Jurgi Camblong · Executive Chairman · listed since Jul 2026
Changes in the last 10 years (19)
| Jul 7, 2026 | Ross Muken listed as Chief Executive Officer (previously President) in SEC filings |
| Jul 7, 2026 | Ross Muken first listed as a director in an SEC filing |
| Jul 1, 2026 | Jurgi Camblong listed as Executive Chairman (previously Chief Executive Officer) in SEC filings |
| Mar 18, 2026 | Zhenyu Xu became Chief Scientific Officer |
| Mar 18, 2026 | Vincent Ossipow became a director |
| Mar 18, 2026 | Troy Cox became a director |
| Mar 18, 2026 | Tomer Berkovitz became a director |
| Mar 18, 2026 | Ross Muken became President |
| Mar 18, 2026 | Philippe Menu became Chief Medical Officer |
| Mar 18, 2026 | Manuela Valente became Chief People Officer |
| Mar 18, 2026 | Kevin Puylaert became Chief Sales Officer |
| Mar 18, 2026 | Kathy L Hibbs became a director |
| Mar 18, 2026 | Jurgi Camblong became a director |
| Mar 18, 2026 | Jurgi Camblong became Chief Executive Officer |
| Mar 18, 2026 | Jean-Michel Cossery became a director |
| Mar 18, 2026 | George Cardoza became Chief Financial Officer |
| Mar 18, 2026 | Didier Hirsch became a director |
| Mar 18, 2026 | Daan Van Well became Chief Legal Officer |
| Mar 18, 2026 | Abhimanyu Verma became Chief Technology Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SOPH Proposed Insider Sales (Form 144)
Latest: 2026-10-05
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
15 filings
· $1.6M notice value
· 8 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
JURGI CAMBLONG (1, $530K) · ZHENYU XU (4, $387K) · PHILIPPE MENU (1, $181K) · KATHY L HIBBS (1, $158K) · MANUELA VALENTE (2, $110K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-05 | ZHENYU XU | Officer | 19,394 | $156.5K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | DAAN GUIDO MARIA VAN WELL | Officer | 6,168 | $49.8K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | ROSS J MUKEN | Director, Officer | 9,838 | $79.4K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | PHILIPPE MENU | Officer | 22,394 | $180.7K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | MANUELA VALENTE | Officer | 4,240 | $34.2K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | GEORGE CARDOZA | Officer | 1,592 | $12.8K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-10-05 | JURGI CAMBLONG | Director, Officer | 65,672 | $530.0K | 2026-10-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-21 | GEORGE CARDOZA | Officer | 774 | $6.3K | 2026-09-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-21 | ROSS J MUKEN | Director, Officer | 422 | $3.5K | 2026-09-21 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-11 | DAAN GUIDO MARIA VAN WELL | Officer | 6,168 | $46.9K | 2026-09-11 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold SOPH
3 shown · $700.86K total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $383,344 | $10.0B | 2026-11-05 |
| 2 | GWX State Street® SPDR® S&P® International Small Cap ETF | SPDR (State Street) | 0.03% | $310,473 | $896.1M | 2026-11-05 |
| 3 | GNMX Corgi Genomics & Precision Medicine ETF | Corgi | 0.55% | $7,047 | $1.3M | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (5 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | — | — | — | — |
| Q4 '24 | 2024-12-31 | — | — | — | — |
| Q4 '23 | 2023-12-31 | — | — | — | — |
| Q4 '22 | 2022-12-31 | — | — | — | — |
| Q4 '21 | 2021-12-31 | — | — | — | — |
Q4 2025 • period ending 2025-12-31 • filed 2026-03-03
SOPH vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific, Inc. | $257.4B | 37.9 | +8.3% | +21.3% | 48 |
| VRTX Vertex Pharmaceuticals Inc | $138.7B | 35.4 | +10.5% | +21.8% | 60 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +795.8% | 51 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +151.8% | 66 |
| GMAB Genmab A/S ADS | $33.0B | — | — | +73.2% | 19 |
| ILMN Illumina Inc | $32.2B | 38.1 | +5.8% | +65.0% | 55 |
| TEM Tempus AI, Inc. Class A Common Stock | $13.9B | — | +36.6% | +36.5% | 70 |
| CERT Certara, Inc. Common Stock | $1.8B | — | +2.3% | +42.6% | 16 |
| SOPH SOPHiA GENETICS SA Ordinary Shares | $612M | — | — | +60.7% | 5 |
| Peer median | $37.3B | 37.9 | +7.1% | +53.8% | 53 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.00M
SI % of Float
1.96%
Days to Cover
1.45
Short Vol Ratio
62.9%
Free Float
50.90M
Float %
60.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14